ABRAHAM, J. Pharmaceuticalization of society in context: theoretical, empirical and health dimensions. Sociology, London, v. 44, n. 4, p. 603-622, 2010.
ANGEL, K. Contested psychiatric ontology and feminist critique: ‘Female Sexual Dysfunction’ and the Diagnostic and Statistical Manual. History of the Human Sciences, London, v. 25, n. 4, p. 3-24, 2012.
ANGELL, M. A verdade sobre os laboratórios farmacêuticos. 5. ed. Rio de Janeiro: Record, 2010.
BEKELMAN, J.; LI, Y.; GROSS, C. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA, Chicago, v. 289, n. 4, p. 22-29, Jan. 2003.
BELL, R. et al. Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause: The Journal of the North American Menopause Society, New York, v. 13, n. 1, p. 65-71, 2006.
BELL, S.; FIGERT, A. Medicalization and pharmaceuticalization at the intersections: looking backward, sideways and forward. Social Science & Medicine, Oxford, v. 75, n. 5, p. 775-783, 2012.
CACCHIONI, T. Big pharma, women, and the labour of love. Toronto: University of Toronto Press, 2015.
CAMARGO Jr., K. Medicalização, farmacologização e imperialismo sanitário. Cadernos de Saúde Pública, Rio de Janeiro, v. 29, n. 5, p. 844-846, maio 2013.
CHAZAN, L.; FARO, L. “Exame bento” ou “foto do bebê”? Biomedicalização e estratificação nos usos do ultrassom obstétrico no Rio de Janeiro. História, Ciências, Saúde – Manguinhos, Rio de Janeiro, v. 23, n. 1, p. 57-78, 2016.
CLARKE, A. et al. Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine. American Sociological Review, New York, v. 68, n. 2, p. 161-194, Apr. 2003.
CLARKE, A. et al. (Ed.). Biomedicalization: technoscience, health and illness in the U.S. Durkham: Duke University Press, 2010.
CONRAD, P. The shifting engines of medicalization. Journal of Health and Social Behavior, Thousand Oaks, v. 46, n. 1, p. 3-14, 2005.
CONRAD, P. The medicalization of society: on the transformation of human conditions into treatable disorders. Baltimore: The Johns Hopkins University Press, 2007.
DAVIS, S. et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, Amsterdam, v. 21, p. 227-236, 1995.
DAVIS, S. et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause: The Journal of the North American Menopause Society, New York, v. 13, n. 3, p. 387-396, 2006.
DAVIS, S. et al. Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medecine, Boston, v. 359, n. 19, p. 2005-2017, 2008.
DUMIT, J. Drugs for life: how pharmaceutical companies define our health. Durham: Duke University Press, 2012.
FALLON, B. “Off-label” drug use in sexual medicine treatment. International Journal of Impotence Research, London, v. 20, p. 127-134, 2008.
FARO, L. As disfunções sexuais femininas no periódico Archives of Sexual Behavior. 2008. Dissertação (Mestrado em Saúde Coletiva)–Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2008.
FARO, L. et al. “Homem com “H”: ideais de masculinidade (re)construídos no marketing farmacêutico. Cadernos Pagu, Campinas, n. 40, p. 287-321, 2013.
FISHMAN, J. Desire for profit: Viagra and the remaking of sexual function. 2003. Dissertation (Doctor of Philosophy in Sociology)–Department of Social and Behavioral Sciences, University of California, San Francisco, 2003.
FISHMAN, J. Manufacturing desire: the co modification of female sexual dysfunction. Social Studies of Science, London, v. 34, n. 2, p. 187-218, 2004.
FISHMAN, J. The making of Viagra: the biomedicalization of sexual dysfunction. In: CLARKE, A. et al. (Ed.). Biomedicalization: technoscience, health and illness in the U.S. Durkham: Duke University Press, 2010. p. 289-306.
FISHMAN, J.; MAMO, L. What’s in a disorder: a cultural analysis of medical and pharmaceutical constructions of male and female sexual dysfunction. Women & Therapy, Abingdon, v. 24, n. 1-2, p. 179-193, 2001.
FOUCAULT, M. História da sexualidade I: a vontade de saber. Rio de Janeiro: Graal, 1988.
FOX, N.; WARD, K. Pharma in the bedroom… and the kitchen…. The pharmaceuticalisation of daily life. Sociology of Health & Illness, Hoboken, v. 30, n. 6, p. 856-868, 2008.
GEIST, S.; SALMON, U. Androgen therapy in gynecology. JAMA, Chicago, v. 117, n. 26, p. 2207-2215, 1941.
GIAMI, A. Permanência das representações do gênero em sexologia: as inovações científica e médica comprometidas pelos estereótipos de gênero. Physis: Revista de Saúde Coletiva, Rio de Janeiro, v. 17, n. 2, p. 301-320, 2007.
GIAMI, A. Da impotência à disfunção erétil. Destinos da medicalização da sexualidade. Physis: Revista de Saúde Coletiva, Rio de Janeiro, v. 19, n. 3, p. 637-658, 2009.
GOLDSTAT, E. et al. Transdermal testosterone therapy improves well-being, mood and sexual function in premenopausal women. Menopause: The Journal of the North American Menopause Society, New York, v. 10, n. 5, p. 390-398, 2003.
HARAWAY, D. Modest_Witness@Second_Millennium. FemaleMan©_Meets_OncoMouse™: feminism and technoscience. New York: Routledge, 1997.
HEALY, D. The anti-depressant era. Cambridge: Harvard University Press, 1997.
HEALY, D. The new medical Oikumene. In: PETRYNA, A.; LAKOFF, A.; KLEINMAN, A. (Ed.). Global pharmaceuticals: ethics, markets, practices. Durham: Duke University Press, 2006. p. 61-84.
HEALY, D. Pharmageddon. Berkeley: University of California Press, 2012.
HOBERMAN, J. Testosterone dreams: rejuvenation, aphrodisia, doping. Berkeley: University of California Press, 2005.
HOUCK, J. The medicalization of menopause in America, 1897–2000: mapping the terrain. In: KLEINMAN, D.; KINCHY, A.; HANDELSMAN, J. Controversies in science and technology: from maize to menopause. Madison: The University of Wisconsin Press, 2005. p. 198-218.
JASANOFF, S. States of knowledge: the co-production of science and social order. New York: Routledge, 2004.
KAPLAN, H.; OWETT, T. The Female Androgen Deficiency Syndrome. Journal of Sex & Marital Therapy, Abingdon, v. 19, n. 1, p. 3-24, 1993.
KRIEGER, N. et al. Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives. Journal of Epidemiology and Community Health, London, v. 59, n. 9, p. 740-748, 2005.
LAKOFF, A. High contact: gifts and surveillance in Argentina. In: PETRYNA, A.; LAKOFF, A.; KLEINMAN, A. (Ed.). Global pharmaceuticals: ethics, markets, practices. Durham: Duke University Press, 2006. p. 111-135.
LATOUR, B. Ciência em ação: como seguir cientistas e engenheiros sociedade afora. São Paulo: Editora Unesp, 2000.
LOE, M. The rise of Viagra: how the little blue pill changed sex in America. New York: New York University Press, 2004.
LYKKE, N. Introduction. In: LYKKE, N.; BRAIDOTTI, R. (Ed.). Between monsters, goddesses & cyborgs: feminist confrontations with science, medicine and cyberspace. London: Zed Books, 1996.
LYKKE, N. Feminist cultural studies of technoscience: portrait of an implosion. In: SMELIK, A.; LYKKE, N. (Ed.). Bits of life: feminism at the intersections of media, bioscience, and technology. Seattle: University of Washington Press, 2008. p. 3-15.
MANICA, D. Contracepção, natureza e cultura: embates e sentidos na etnografia de uma trajetória. 2009. Tese (Doutorado em Antropologia Social)–Instituto de Filosofia e Ciências Humanas, Universidade Estadual de Campinas, Campinas, 2009.
MARSHALL, B. The new virility: Viagra, male aging and sexual function. Sexualities, London, v. 9, n. 3, p. 345-362, 2006.
MICHAELS, D. Doubt is their product: how industry’s assault on science threatens your health. New York: Oxford University Press, 2008.
MIGUELOTE, V.; CAMARGO Jr., K. Indústria do conhecimento: uma poderosa engrenagem. Revista de Saúde Pública, São Paulo, v. 44, n. 1, p. 190-196, 2010.
MOYNIHAN, R. Disease-mongers: how doctors, drug companies, and insurers are making you feel sick. British Medical Journal, London, v. 324, n. 7342, p. 923, 2002.
MOYNIHAN, R. FDA panel rejects testosterone patch for women on safety grounds. British Medical Journal, London, v. 329, n. 7479, p. 1363, 2004.
MOYNIHAN, R.; CASSELS, A. Selling sickness. New York: Nation Books, 2005.
MOYNIHAN, R.; MINTZES, B. Sex, lies and pharmaceuticals: how drug companies plan to profit from female sexual dysfunction. Vancouver: Greystone, 2010.
OSBORNE, V. et al. Drug utilization of INTRINSA® (TESTOSTERONE patch) in England: interim analysis of a prescription-event monitoring study to support risk management. Pharmacoepidemiology and Drug Safety, Hoboken, v. 33, n. 3, p. 213-221, 2010.
OUDSHOORN, N. Beyond the natural body: an archeology of sex hormones. London: Routledge, 1994.
PALACE, E.; GORZALKA, B. Differential patterns of arousal in sexually functional and dysfunctional women: physiological and subjective components of sexual response. Archives of Sexual Behavior, New York, v. 21, n. 2, p. 135-159, 1992.
PETRYNA, A. Globalizing human subjects research. In: PETRYNA, A.; LAKOFF, A.; KLEINMAN, A. (Ed.). Global pharmaceuticals: ethics, markets, practices. Durham: Duke University Press, 2006. p. 33-60.
PETRYNA, A.; LAKOFF, A.; KLEINMAN, A. (Ed.). Global pharmaceuticals: ethics, markets, practices. Durham: Duke University Press, 2006.
ROHDEN, F. “O homem é mesmo a sua testosterona”: promoção da andropausa e representações sobre sexualidade e envelhecimento no cenário brasileiro. Horizontes Antropológicos, Porto Alegre, ano 17, n. 35, p. 161-196, 2011.
ROHDEN, F. A criação da andropausa no Brasil: articulações entre ciência, mídia e mercado e redefinições de sexualidade e envelhecimento. Psicología, Conocimiento y Sociedad, Montevideo, v. 2, p. 196-219, 2012.
ROSE, N. The politics of life itself: biomedicine, power, subjectivity in the twenty-first century. Princeton: Princeton University Press, 2007.
RUSSO, J. A terceira onda sexológica: medicina sexual e farmacologização da sexualidade. Sexualidad, Salud y Sociedad, Rio de Janeiro, n. 14, p. 172-194, 2013.
SANABRIA, E. From sub- to super-citizenship: sex hormones and the body politic in Brazil. Ethnos: Journal of Anthropology, Abingdon, v. 75, n. 4, p. 377-401, 2010.
SCHNITTKER, J. Mirage of health in the era of biomedicalization: evaluating change in the threshold of illness, 1972-1996. Social Forces, Chapel Hill, v. 87, n. 4, p. 2155-2182, June 2009.
SCOTT, S. The medicalisation of shyness: from social misfits to social fitness. Sociology of Health & Illness, Hoboken, v. 28, n. 2, p. 133-153, Mar. 2006.
SHIFREN, J. et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New England Journal of Medecine, Boston, v. 343, p. 682-688, 2000.
SHIFREN, J. et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause, New York, v. 13, n. 5, p. 770-779, Sept./Oct. 2006.
SISMONDO, S. Ghosts in the machine: publication planning in the medical sciences. Social Studies of Science, London, v. 39, n. 2, p. 171-198, 2009.
SMITH, R. Medical journals are an extension of the marketing arm of pharmaceutical companies. Plos Medicine, San Francisco, v. 2, n. 5, 2005.
SPURGAS, A. Interest, arousal, and shifting diagnoses of female sexual dysfunction, or: how women learn about desire. Studies in Gender and Sexuality, Hillsdale, v. 14, n. 13, p. 187-205, 2013.
SPURGAS, A. Low desire, trauma and femininity in the DSM-5: a case for sequelae. Psychology & Sexuality, Abingdon, v. 7, n. 1, p. 48-67, 2015.
THIAGO, C. Hormônios, masculinidade e velhice: um estudo de sites de laboratórios farmacêuticos e associações médico-científicas. 2012. Dissertação (Mestrado em Saúde Coletiva)–Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2012.
TIEFER, L. The “consensus” conference on female sexual dysfunction: conflicts of interests and hidden agendas. Journal of Sex & Marital Therapy, Abingdon, v. 27, n. 2, p. 227-236, 2001.
TIEFER, L. Female sexual dysfuncion: a case study of disease mongering and activist resistance. Plos Medicine, San Francisco, v. 3, n. 4, p. 436-440, 2006.
TIMMERMANS, S. The joy of science: finding success in a “failed” randomized clinical trial. Science, Technology & Human Values, Cambridge, v. 36, n. 4, p. 549-572, 2011.
TRAMONTANO, L. “Continue a nadar”: sobre testosterona, envelhecimento e masculinidade. 2012. Dissertação (Mestrado em Saúde Coletiva)–Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, 2012.
TUITEN, A. et al. Discrepancies between genital responses and subjective sexual function during testosterone substitution in women with hypothalamic amenorrhea. Psychosomatic Medicine, Philadelphia, v. 58, n. 3, p. 234-241, 1996.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for industry: female sexual dysfunction: clinical development of drug products for treatment. [S.l.], 2000. Disponível em: <http://www.rsihata.com/updateguidance/usfda2/2005-1/3312dft.pdf>. Acesso em: 26 fev. 2016.
WARNOCK, J.; BUNDREN, J.; MORRIS, D. Female hypoactive sexual desire disorder due to androgen deficiency: clinical and psychometric issues. Psychopharmacology Bulletin, Bethesda, v. 33, n. 4, p. 761-766, 1997.
WASSERTHEIL-SMOLLER, S. Postmenopausal hormones: an overview. In: KLEINMAN, D.; KINCHY, A.; HANDELSMAN, J. Controversies in science and technology: from maize to menopause. Madison: The University of Wisconsin Press, 2005. p. 181-197.
WILLIAMS, S. J.; MARTIN, P.; GABE, J. The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness, Hoboken, v. 33, n. 5, p. 710-725, 2011.